Literature DB >> 26676779

Membrane Binding of the Rous Sarcoma Virus Gag Protein Is Cooperative and Dependent on the Spacer Peptide Assembly Domain.

Robert A Dick1, Marilia Barros2, Danni Jin3, Mathias Lösche4, Volker M Vogt3.   

Abstract

UNLABELLED: The principles underlying membrane binding and assembly of retroviral Gag proteins into a lattice are understood. However, little is known about how these processes are related. Using purified Rous sarcoma virus Gag and Gag truncations, we studied the interrelation of Gag-Gag interaction and Gag-membrane interaction. Both by liposome binding and by surface plasmon resonance on a supported bilayer, Gag bound to membranes much more tightly than did matrix (MA), the isolated membrane binding domain. In principle, this difference could be explained either by protein-protein interactions leading to cooperativity in membrane binding or by the simultaneous interaction of the N-terminal MA and the C-terminal nucleocapsid (NC) of Gag with the bilayer, since both are highly basic. However, we found that NC was not required for strong membrane binding. Instead, the spacer peptide assembly domain (SPA), a putative 24-residue helical sequence comprising the 12-residue SP segment of Gag and overlapping the capsid (CA) C terminus and the NC N terminus, was required. SPA is known to be critical for proper assembly of the immature Gag lattice. A single amino acid mutation in SPA that abrogates assembly in vitro dramatically reduced binding of Gag to liposomes. In vivo, plasma membrane localization was dependent on SPA. Disulfide cross-linking based on ectopic Cys residues showed that the contacts between Gag proteins on the membrane are similar to the known contacts in virus-like particles. Taken together, we interpret these results to mean that Gag membrane interaction is cooperative in that it depends on the ability of Gag to multimerize. IMPORTANCE: The retroviral structural protein Gag has three major domains. The N-terminal MA domain interacts directly with the plasma membrane (PM) of cells. The central CA domain, together with immediately adjoining sequences, facilitates the assembly of thousands of Gag molecules into a lattice. The C-terminal NC domain interacts with the genome, resulting in packaging of viral RNA. For assembly in vitro with purified Gag, in the absence of membranes, binding of NC to nucleic acid somehow facilitates further Gag-Gag interactions that lead to formation of the Gag lattice. The contributions of MA-mediated membrane binding to virus particle assembly are not well understood. Here, we report that in the absence of nucleic acid, membranes provide a platform that facilitates Gag-Gag interactions. This study demonstrates that the binding of Gag, but not of MA, to membranes is cooperative and identifies SPA as a major factor that controls this cooperativity.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26676779      PMCID: PMC4810714          DOI: 10.1128/JVI.02733-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  73 in total

1.  Nuclear entry and CRM1-dependent nuclear export of the Rous sarcoma virus Gag polyprotein.

Authors:  Lisa Z Scheifele; Rachel A Garbitt; Jonathan D Rhoads; Leslie J Parent
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

2.  Gag localization and virus-like particle release mediated by the matrix domain of human T-lymphotropic virus type 1 Gag are less dependent on phosphatidylinositol-(4,5)-bisphosphate than those mediated by the matrix domain of HIV-1 Gag.

Authors:  Jingga Inlora; Vineela Chukkapalli; David Derse; Akira Ono
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

3.  Rous sarcoma virus gag has no specific requirement for phosphatidylinositol-(4,5)-bisphosphate for plasma membrane association in vivo or for liposome interaction in vitro.

Authors:  Jany Chan; Robert A Dick; Volker M Vogt
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

4.  Directionality of nucleocytoplasmic transport of the retroviral gag protein depends on sequential binding of karyopherins and viral RNA.

Authors:  Nicole Gudleski; John M Flanagan; Eileen P Ryan; Maria C Bewley; Leslie J Parent
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-30       Impact factor: 11.205

5.  Rous sarcoma virus Gag protein-oligonucleotide interaction suggests a critical role for protein dimer formation in assembly.

Authors:  Yu May Ma; Volker M Vogt
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

6.  HIV-1 Gag protein can sense the cholesterol and acyl chain environment in model membranes.

Authors:  Robert A Dick; Shih Lin Goh; Gerald W Feigenson; Volker M Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-24       Impact factor: 11.205

7.  Analysis of human immunodeficiency virus type 1 matrix binding to membranes and nucleic acids.

Authors:  Ayna Alfadhli; Amelia Still; Eric Barklis
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

8.  Opposing mechanisms involving RNA and lipids regulate HIV-1 Gag membrane binding through the highly basic region of the matrix domain.

Authors:  Vineela Chukkapalli; Seung J Oh; Akira Ono
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

9.  Interaction between the human immunodeficiency virus type 1 Gag matrix domain and phosphatidylinositol-(4,5)-bisphosphate is essential for efficient gag membrane binding.

Authors:  Vineela Chukkapalli; Ian B Hogue; Vitaly Boyko; Wei-Shau Hu; Akira Ono
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

10.  Live-cell observation of cytosolic HIV-1 assembly onset reveals RNA-interacting Gag oligomers.

Authors:  Jelle Hendrix; Viola Baumgärtel; Waldemar Schrimpf; Sergey Ivanchenko; Michelle A Digman; Enrico Gratton; Hans-Georg Kräusslich; Barbara Müller; Don C Lamb
Journal:  J Cell Biol       Date:  2015-08-17       Impact factor: 10.539

View more
  7 in total

1.  Membrane Binding of HIV-1 Matrix Protein: Dependence on Bilayer Composition and Protein Lipidation.

Authors:  Marilia Barros; Frank Heinrich; Siddhartha A K Datta; Alan Rein; Ioannis Karageorgos; Hirsh Nanda; Mathias Lösche
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

2.  Effects of Membrane Charge and Order on Membrane Binding of the Retroviral Structural Protein Gag.

Authors:  Yi Wen; Robert A Dick; Gerald W Feigenson; Volker M Vogt
Journal:  J Virol       Date:  2016-09-29       Impact factor: 5.103

3.  Phosphatidylinositol 4,5-Bisphosphate-Dependent Oligomerization of the Pseudomonas aeruginosa Cytotoxin ExoU.

Authors:  Angelica Zhang; Jeffrey L Veesenmeyer; Alan R Hauser
Journal:  Infect Immun       Date:  2017-12-19       Impact factor: 3.441

4.  Structural basis for targeting avian sarcoma virus Gag polyprotein to the plasma membrane for virus assembly.

Authors:  Jiri Vlach; Gunnar N Eastep; Ruba H Ghanam; Susan M Watanabe; Carol A Carter; Jamil S Saad
Journal:  J Biol Chem       Date:  2018-10-11       Impact factor: 5.157

5.  Structures of immature EIAV Gag lattices reveal a conserved role for IP6 in lentivirus assembly.

Authors:  Robert A Dick; Chaoyi Xu; Dustin R Morado; Vladyslav Kravchuk; Clifton L Ricana; Terri D Lyddon; Arianna M Broad; J Ryan Feathers; Marc C Johnson; Volker M Vogt; Juan R Perilla; John A G Briggs; Florian K M Schur
Journal:  PLoS Pathog       Date:  2020-01-27       Impact factor: 6.823

6.  An Infectious Rous Sarcoma Virus Gag Mutant That Is Defective in Nuclear Cycling.

Authors:  Clifton L Ricaña; Marc C Johnson
Journal:  J Virol       Date:  2021-07-28       Impact factor: 5.103

7.  Cholesterol Promotes Protein Binding by Affecting Membrane Electrostatics and Solvation Properties.

Authors:  Milka Doktorova; Frederick A Heberle; Richard L Kingston; George Khelashvili; Michel A Cuendet; Yi Wen; John Katsaras; Gerald W Feigenson; Volker M Vogt; Robert A Dick
Journal:  Biophys J       Date:  2017-11-07       Impact factor: 3.699

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.